Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P D Nathan

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2014
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanomaA Gupta, S Love, A Schuh, et al.
British Journal of Cancer|July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen, R Marais, A Affolter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2014
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanomaA Gupta, S Love, A Schuh, et al.
British Journal of Cancer|July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen, R Marais, A Affolter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 2